<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene K417N literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.K417N</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Causes no detectable change in KD value for antibody binding of P22A-1D1.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Causes no detectable change in KD value for antibody binding of P5A-1D2.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Causes 1.5 fold decrease in KD value of antibody binding of ACE2.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.<br/> (<a href="https://doi.org/10.1101/2021.05.18.444646" class="lit_link">Barton et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd = 145.1nM vs 56.9nM).<br/> (<a href="https://doi.org/10.1101/2021.02.14.431117" class="lit_link">Tian et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> No detectable fold drop in IC50 of P22A-1D1.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> No detectable fold drop in IC50 of P5A-1D2.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> No detectable fold drop in IC50 of P5A-3C8.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 1.1 fold drop in IC50 of P2C-1F11.<br/> (<a href="https://doi.org/10.1038/s41467-021-24514-w" class="lit_link">Zhang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> >20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.<br/> (<a href="https://doi.org/10.1101/2021.03.22.436481" class="lit_link">Sun et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs) (<a href="https://doi.org/10.1101/2021.01.15.426911" class="lit_link">Wang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD).<br/>Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933. (<a href="https://doi.org/10.1038/s41586-021-03398-2" class="lit_link">Wang et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistance P=0.0361.<br/> (<a href="https://doi.org/10.1038/s41591-021-01294-w" class="lit_link">Chen et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="gene_expression_increase">Gene expression increase</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Experimentally, Spike gene expression increased 0.1 fold (<a href="https://doi.org/10.1016/j.cell.2020.08.012" class="lit_link">Starr et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Escape mutation against monoclonal antibody LY-CoV016 (<a href="https://doi.org/10.1101/2021.02.17.431683" class="lit_link">Starr et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660 (<a href="https://doi.org/10.1101/2021.01.15.426911" class="lit_link">Wang et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> COR-101 lost ~6x binding against this isolated mutation.<br/>Estesevimab lost ~100x binding against this isolated mutation. (<a href="https://doi.org/10.1101/2021.04.27.440939" class="lit_link">Engelhart et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="trafficking">Trafficking</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.<br/> (<a href="https://doi.org/10.1101/2021.02.05.430003" class="lit_link">Tada et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="virion_structure">Virion structure</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type)  (<a href="https://doi.org/10.1101/2021.03.24.436850" class="lit_link">Spratt et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
